












"8 New Square brims with barristers experienced in fighting fiendishly complex, high-value IT and telecoms disputes."
Chambers & Partners 2014
'An incredibly good set for IP matters'.
Legal 500 2010
"8 New Square brims with barristers experienced in fighting fiendishly complex, high-value IT and telecoms disputes."
Chambers & Partners (Information Technology) 2014
'Practical and helpful clerks" provide a "smooth and personable service.'
Chambers and Partners 2011
"8 New Square is undoubtedly one of the leading sets for trade mark and copyright cases within the media and entertainment sphere, so much so that stablemates here frequently find themselves pitted against each other in major cases."
Chambers & Partners (Media & Entertainment) 2014
'A number of great IT and telecoms barristers.'
Legal 500 2010
"an impressive set with quality from the top
silk down to the most junior barristers."
Chambers & Partners (Information Technology) 2013
The clerks are described as "helpful," "generous" and "very good at knowing what you want."
Chambers & Partners (Intellectual Property) 2013
'Top drawer IP set.'
Legal 500 2010
"Fantastic roster of talent" and recommended for being "very modern, forward-thinking and providing sound commercial advice" as well as offering instructing solicitors "a very broad skill set in the soft IP space."
Chambers & Partners 2017
"There are great people there at all levels and the clerks are very accommodating."
Chambers & Partners (Intellectual property) 2014
'excellence on IT matters'
Legal 500 (Information Technology) 2010
'A veritable powerhouse of IP expertise'
Chambers and Partners 2011
Merck Canada Inc v Sigma Pharmaceuticals PLC [2013] EWCA Civ 326
Case Summary | Judgment | 18 April 2013
Martin Howe QC and Isabel Jamal acted for the appellants in successfully persuading the Court of Appeal to make a preliminary reference on the interpretation of the so-called ‘Specific Mechanism’, which relates to the parallel importation of pharmaceuticals from Poland and other EU Accession States. The case was decided at first instance ([2012] EWPCC 18, HHJ Birss QC) without a reference.
Sigma notified Merck of its intention to import a Merck drug called Singulair from Poland asking whether Merck had any objection. Merck did not reply as a result of an administrative oversight. Sigma went ahead and imported and sold large quantities of Singulair until Merck objected at which point it stopped. The Specific Mechanism in Poland’s Act of Accession to the EU creates an exception to the normal EU free movement rules. It allows drug patent or SPC holders in the existing Member States to enforce them against parallel imports when they could not have obtained corresponding protection under Polish law. It also requires the patent holder or his beneficiary to be notified at least one month before the import licence is applied for. The Court of Appeal’s questions to the ECJ will ask whether there has to be a prior demonstration by the patent holder of its intention to invoke the Specific Mechanism before parallel importations are to be treated as infringing acts; and also by whom and to whom the notification should be given, since in this case it was given by another company in Sigma’s group, and was sent to Merck’s operating subsidiary in the UK rather than to its Canadian subsidiary which was the registered proprietor of the patent.